Addex Therapeutics Ltd.
Addex Therapeutics is a Swiss clinical-stage pharmaceutical company headquartered in Geneva. It develops proprietary orally available small-molecule drug candidates, both internally and with partners, for conditions including post-stroke and traumatic brain injury recovery, substance use disorders and chronic cough. Its development programs include dipraglurant, an mGlu5 negative allosteric modulator being evaluated for brain injury recovery; ADX71149, an mGlu2 positive allosteric modulator whose future development Addex is evaluating; and GABAB positive allosteric modulators for substance use disorders and chronic cough. Addex earns money through partner-funded research and licensing arrangements. Indivior has worldwide rights to its selected GABAB candidate for substance use disorders and is responsible for that candidate’s development, manufacture and commercialization. Addex retains an independent GABAB program for chronic cough. It also has an option and collaboration agreement with Sinntaxis AB concerning dipraglurant and holds a 20% equity interest in Neurosterix US Holdings LLC, which develops preclinical drug candidates for schizophrenia and mood disorders.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ADXN in the last 30 days.
See all $ADXN insider activity →Biotech stocks ADXN, ENGN, NTHI, and PRQR rose significantly. ADXN surged 71% after its spin-out Neurosterix raised $105M. ENGN gained 26% with new executive appointments. NTHI rose 13% following FDA meeting news. PRQR increased 10% on strong revenue growth and clinical progress.
Addex Therapeutics' spin-out, Neurosterix, raised $105M in Series B funding. Addex holds an 8.5% stake valued at $18.6M. Funds will support Phase 2 development of NTX-253, following completed Phase 1 studies.
Addex Therapeutics issued 93 million new shares to its subsidiary, increasing total issued shares to 311.65 million. Outstanding shares remain unchanged. The move is intended to facilitate future funding without immediate dilution, according to the company.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ADXN (Addex Therapeutics Ltd.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ADXN coverage spans financial news, earnings and insider activity.
Strong financing boost expected to fund Phase 2 trials and expand pipeline.
Addex Therapeutics' spin-out, Neurosterix, raised $105M in Series B funding. Addex holds an 8.5% stake valued at $18.6M. Funds will support Phase 2 development of NTX-253, following completed Phase 1 studies.
Addex Therapeutics issued 93 million new shares to its subsidiary, increasing total issued shares to 311.65 million. Outstanding shares remain unchanged. The move is intended to facilitate future funding without immediate dilution, according to the company.
Addex Therapeutics (APE) announced that its 20%-owned spin-out, Neurosterix, completed Phase 1 studies of NTX-253 and plans to advance it into Phase 2 trials for schizophrenia.
Addex Therapeutics (APE) appointed Jean-Philippe Rocher to its executive management team as Head of Pharmaceutical Development, while Mikhail Kalinichev left his role as Head of Translational Science. The changes aim to advance the company's clinical-ready programs. According to AI Analyst, significant catalysts could include trial initiations, positive data, or partnering milestones under the new leadership.
AlphAI scores every news story that mentions ADXN with an AI model for sentiment and relevance, and aggregates insider trades from Addex Therapeutics Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech stocks ADXN, ENGN, NTHI, and PRQR rose significantly. ADXN surged 71% after its spin-out Neurosterix raised $105M. ENGN gained 26% with new executive appointments. NTHI rose 13% following FDA meeting news. PRQR increased 10% on strong revenue growth and clinical progress.
Addex Therapeutics' spin-out, Neurosterix, raised $105M in Series B funding. Addex holds an 8.5% stake valued at $18.6M. Funds will support Phase 2 development of NTX-253, following completed Phase 1 studies.
Addex Therapeutics issued 93 million new shares to its subsidiary, increasing total issued shares to 311.65 million. Outstanding shares remain unchanged. The move is intended to facilitate future funding without immediate dilution, according to the company.
Addex Therapeutics (APE) announced that its 20%-owned spin-out, Neurosterix, completed Phase 1 studies of NTX-253 and plans to advance it into Phase 2 trials for schizophrenia.
Addex Therapeutics (APE) appointed Jean-Philippe Rocher to its executive management team as Head of Pharmaceutical Development, while Mikhail Kalinichev left his role as Head of Translational Science. The changes aim to advance the company's clinical-ready programs. According to AI Analyst, significant catalysts could include trial initiations, positive data, or partnering milestones under the new leadership.
Addex (ADXN) reported a H1 2026 net loss of CHF 3.5M, with cash reserves of CHF 767K. It raised USD 2.8M in capital and regained rights to its GABAB PAM portfolio. The company expects NTX-253 to complete Phase 1 trials by Q4 2026 and is preparing dipraglurant for Phase 2 trials in post-stroke recovery. Management expressed uncertainty about the company's ability to continue as a going concern.
Addex Therapeutics Ltd. (ADXN) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 PRESS RELEASE Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical co
Addex Therapeutics (ADXN) will report Q2 2026 results on September 28, 2026. Q1 2026 saw a net loss of CHF 1.71 million, with R&D and admin expenses down. Neurosterix, a spin-out, is advancing NTX-253 for schizophrenia. ADXN raised $2.8 million in August 2026, extending cash runway. Q2 2025 had a net loss of CHF 1.84 million. ADXN stock is at $3.45.
Kalinichev Mikhail (HEAD OF TRANSLATIONAL SCIENCE) sold (to issuer) 306,765 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
Nunn Jason Raleigh sold (to issuer) 219,561 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
